Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
nope, no pump and dump here. Volume is not high enough. It's going up and down because there isn't a lot of attention on this. It can fly up to 1.90s just like that, but also drop down to 1.60's just as fast. If you watch lvl2 throughout the day we don't have very high asks or bids. I just keep loading on the dips.
nope, no pump and dump here. Volume is not high enough. It's going up and down because there isn't a lot of attention on this. It can fly up to 1.90s just like that, but also drop down to 1.60's just as fast. If you watch lvl2 throughout the day we don't have very high asks or bids. I just keep loading on the dips.
Why is this stock going up and down like crazy? I hope it's not a pump and dump.
At first I thought it was someones stop loss order in place, but then after looking at it, it dropped down over a few minutes. I bought more thinking this would shoot right back up but that's not the case. I hope this holds $1.60
Same here, wtf
3 DAY UP PATTERN
Monday should be fun :)
Looking very good here folks. I'm loving the slow and steady climb. No crazy pump and dumps here. GLTA
Metastat, Inc (OTCQB: MTST) Analyst Report
Analyst Research Report Written by Osman Ghani,
Chartered Financial Analyst
Proud Member of the CFA Institute February 17th, 2014
Ticker: MTST
Recommendation: Buy
Current Price: $1.35 Target Price: $8.18
Highlights:
Metastat is engaged in developing proprietary platform technologies aimed at treating systemic mestastasis.
MTST has products that have been shown to have promising results, and the company is expected to begin revenue generation in 2015, with an expected nationwide rollout of its service by 2018.
We estimate that the current market price is undervalued and that the expected price should be closer to $8.18. This represents a 505% premium over the current market price.
Business Description
Metastat, Inc (OTCQB: MTST) is a life sciences company that provides proprietary platform technologies for the treatment of systemic metastasis. Metastat, Inc. is based in Montclair, New Jersey.
The company’s MetaSite Breast and MenaCalc diagnostic product lines are designed to predict the probability of cancer metastasizing. These are intended to allow clinicians to customize cancer treatment decisions by identifying and differentiating high-risk patients who need aggressive therapy and by sparing low-risk patients from the harmful side effects and expense of chemotherapy and radiation therapies.
The company’s MenaCalc diagnostic platform would also be applicable for various solid epithelial cancers, including breast, prostate, lung, and colorectal. The company’s MenaBloc chemotherapy technology targets and interrupts key pathways essential for the development of systemic metastasis in multiple epithelial derived tumors. The company is also developing MenaBloc therapeutic platform for discovering inhibitors of the mena pathway that can be advanced as anti-cancer therapeutics in multiple epithelial-based tumor types.
MTST has reported no revenue for the last four quarters, but has reported operating losses and net losses totaling $6.22 million during that period. The company’s current market capitalization is $31.7 million, and it has 21.56 million common shares outstanding.
The company has current cash of $488,100 and a current debt balance of $1.86 million.
In September 2013, the company announced that it had commenced its comprehensive drug development program with the hiring of Elizabeth Buck, Ph.D. and Matthew O’Connor, both formerly of OSI Pharmaceuticals, Inc. (acquired by Astellas Pharma, Inc.), along with the opening of its new drug discovery research facility located in Stony Brook, NY. Both Dr. Buck and Mr. O’Connor will work closely and in collaboration with Dr. David Epstein, MetaStat’s Head of Drug Development and former Chief Scientific Officer of OSI Pharmaceuticals. (Access Wire)
In October 2013, the company announced that a study of nearly 500 women with breast cancer showed the predictive ability of the company’s MetaSite Breast test in detecting mestastic disease. (Market Wire)
In December 2013, the company announced that it had entered into two separate exclusive worldwide patent and technology license agreements with The Massachusetts Institute of Technology (“MIT”) and it’s David H. Koch Institute for Integrative Cancer Research at MIT and its Department of Biology, Albert Einstein College of Medicine of Yeshiva University, and Montefiore Medical Center. The Agreements cover the use of alternatively spliced mRNA and protein isoform markers for the diagnosis, prognosis and treatment of metastasis in epithelial solid tumor cancers. (Market Wire)
In December 2013, the company announced that the United States Patent and Trademark Office (USPTO) have issued US Patent Number US 8,603,738. The patent, which expires on July 1, 2029, contains 34 claims that center on the company’s MenaCalc™ diagnostic platform and cover methods for the measurement of the relative levels of the isoforms of the mena protein in cancer cells and the use of such measurement in the diagnosis and prognosis of metastatic cancer.
Overview of the Global Pharmaceuticals Industry
Key features of the Global Pharmaceuticals Industry
According to Market Line, the global pharmaceuticals market grew by 3.5% in 2011 to reach a total value of $782.1 Billion.
According to Market Line, by 2016, the global pharmaceuticals market is expected to have a total value of $971.1 Billion, which represents an increase of 24.2% over the value in 2011.
Within the global pharmaceutical market, the largest segment, representing nearly 42.4% of the total value is the Americas.
Pfizer is the leading company in the global pharmaceutical industry, accounting for nearly 8.7% of the total value.
The market is characterized by strong buyer power, and the ease of market entry is strongly affected by the level of legal and regulatory factors present in each jurisdiction and geographical region.
The global pharmaceuticals market had total revenues of $782.1 Billion in2011, representing a compound annual growth rate (CAGR) of 4.9% between 2007 and 2011. The European and Asia-Pacific markets grew with CAGRs of 3.1% and 8.8% respectively, to reach values of $224.8 billion and $217 billion in 2011.
The performance of the market is forecast to decelerate, with an anticipated CAGR of 4.4% for the five year period 2011-2016, which is expected to drive the market to a value of $971.1 billion by 2016. The European and Asia-Pacific markets will grow with CAGRs of 1.8% and 7.4%, and reach values of $246.2 billion and $310.2 billion in 2016.
Figure 1: Global pharmaceuticals market value (in $Billions)
MTST 1
Figure 2: Geographical Revenues
MTST 2
Figure 3: Global pharmaceuticals market forecast: 2011-2016.
MTST 3
MetaStat’s IP Portfolio:
MTST 4
MetaStat’s Potential Market Size:
Metastatis is responsible for nearly 90% of solid tumor cancer related deaths. However, only a fraction of solid tumors are biologically capable of metastatic spread.
However, the majority of patients suffering from solid tumor cancer cases are treated with aggressive approaches such as chemotherapy or surgery. These patients could potentially be offered less aggressive approaches instead if the particular case of cancer could be properly diagnosed.
MetaStat’s products are meant to bridge this existing gap and are supposed to help in identifying the particular type of tumor and to be able to differentiate between tumors that require more aggressive treatments, versus those cases that may require less aggressive treatments.
The potential market based on MetaStat’s product range is nearly $1.8 billion.
MTST 5
Value of Company
The company has a strategy of 3 phases:
Phase 1 involves targeting 8 cities and will take place in 2015-2016.
Phase 2 involves extending the coverage to a further 12 cities and will commence in 2017.
The final phase is to extend the coverage to the whole of the United States. This is expected to take place in 2018.
The steady state of the company revenue will be achieved by 2018, when the company is forecast to complete 32,000 tests and to achieve revenue of $80 million. This equates to revenue per test of $2,500, which is line with the existing costs of tests which range from $300-$5000.
Using a discount rate of 30% per year, we obtain a discount factor of 0.35 (1/1.3^4).
This gives us a present value of revenue of $28 million today. ($80 million x 0.35).
Using the comparable industry Price/Sales multiple of 6.3x, we obtain a total equity value of $176.5 million.
The outstanding number of shares is 21.56 million; this gives an estimated value per share of $8.18.
This gives us a premium over the current market price of 485%.
Summary
Metastat, Inc (OTCQB: MTST) is a life sciences company that provides proprietary platform technologies for the treatment of systemic metastasis. The company’s MetaSite Breast and MenaCalc diagnostic product lines are designed to predict the probability of cancer metastasizing. These are intended to allow clinicians to customize cancer treatment decisions by identifying and differentiating high-risk patients who need aggressive therapy and by sparing low-risk patients from the harmful side effects and expense of chemotherapy and radiation therapies.
The IP portfolio that MTST has, the proposed revenue generation strategy, and the confidence in MTST’s product range as evidenced by recent academic journals, gives us an estimated price per share of $8.18. This leads us to recommend that the company should be a strong BUY.
disclaimer
Small Cap Street LLC / SmallCapIR.com HAS NEVER and WILL NEVER accept free trading shares on behalf of ANY companies listed at SmallCapIR.com on our email newsletter, or other Social Media.
SmallCapIR.com disclaimer is to be read and fully understood before using SmallCapIR.com, or Joining our SmallCapIR.com Group or Newsletter.
No Tolerance SPAM Policy: We will not sell or re-distribute your Email to any 3rd party. SmallCapIR.com only sends our SmallCapIR.com alert newsletters to opted- in members. If applicable, please unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails.
We are engaged in the business of marketing and advertising companies for monetary compensation. Small Cap Street, LLC has been compensated by Hunter Marketing up to seven thousand five hundred dollars for the mention of MTST. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE WELL: SmallCapIR.com and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this email and/or website advertisement viewing or using you agree to hold SmallCapIR.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur SmallCapIR.com. often receives compensation for marketing, awareness and investor relation services, which can be reviewed within our disclaimer. Compensation for advertised companies constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. SmallCapIR.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and SmallCapIR.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. Further SmallCapIR.com has no advance knowledge of any future events of the profiled companies which includes, but is not limited to, news & press releases, changes in corporate structure, or changes in share structure.
None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead SmallCapIR.com strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. SmallCapIR.com is compliant with the Can Spam Act of 2003. SmallCapIR.com does not offer such advice or analysis, and SmallCapIR.com further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing these publications SmallCapIR.com has relied upon information supplied by various public sources and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Osman Ghani has created and reviewed this report in a best effort manner. SmallCapIR.com has compensated Osman Ghani for the right to disseminate his report in the amount of $100.00. Investors should not rely on the information contained in this email and website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this email and website are believed to be reliable however, SmallCapIR.com and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. SmallCapIR.com is not responsible for any claims made by the companies advertised herein, nor is SmallCapIR.com responsible for any other promotional firm, its program or its structure.
This is not an offer to buy or sell securities. Information or opinions are presented solely for informative purposes, and are not intended nor should they be construed as investment advice. SmallCapIR.com nor any of its employees, affiliates, subsidiaries or family members are registered investment advisors or registered stock brokers and shall not be liable for any direct, indirect, incidental, special or consequential damages arising out of or resulting from the use or inability to use this site, including but not limited to damages for the loss of capital, funds, profits, use, data, or any and all other possible damages, even if such party has been advised of the possibility of such damages resulting from the use of this site and all information contained on this site.
The information provided by SmallCapIR.com is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject us to any registration requirement within such jurisdiction or country.
Information used and statements of fact have been obtained from the featured Company and other sources, but not verified nor guaranteed by SmallCapIR.com as to completeness or accuracy. Such information is subject to change without notice.
All information on featured companies is provided by the companies profiled, or is available from public sources and SmallCapIR.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies.
We remain selective of all of the companies profiled in our newsletter. From time to time we buy shares in the companies profiled. If SmallCapIR.com employees ,owners, or affiliates own shares in a profiled company we may liquidate them immediately after the information is sent to our members. SmallCapIR.com reserves the right to buy or sell shares in the profiled companies any time before during or after the advertisement is sent to our members.
Companies mentioned herein carry a high degree of investment risk; readers should carefully review the companies thoroughly with their registered investment advisor or registered stockbroker. We are not liable for any investment decisions by our readers. We encourage our readers to invest carefully and read the investor information available at the web sites of the U.S. Securities and Exchange Commission (SEC) at www.sec.gov and the National Association of Securities Dealers (NASD) at www.nasd.com.
The NASD has published information on how to invest carefully at its website. Readers can review all public filings by companies at the SEC’s EDGAR page. All information within this website is qualified in its entirety by the detailed information and financial statements of the featured company contained in its regulatory filings with the SEC. The statements contained herein does not purport to be a complete study of the featured Company or other companies mentioned.
Yup. I am expecting a double up by next week.
This thing is a gem guys. PV$T replay :)
Very pleased with this play so far, slow n steady always makes PROFIT$$$$$$
Finally getting some attention on IHub. I saw the news this morning and check the board but we didn't have a message board at the time.
Very low float, only 28 million. This thing will explode passing the $10 IMO.
me too I loaded up 2k shares as a starter.
The close was very strong, the volume is monsterous compared to their daily avg.
Difinetly $5+ by the EOW
Just loaded up this morning, got the news alert through PVCT. thought I would give this one a shot as well.. GO GO GO
This is a monster is infancy phase people, exclusive contracts with MIT and patents already.
Product is the market early 2015.
Followers
|
9
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
76
|
Created
|
02/18/14
|
Type
|
Free
|
Moderators |
MetaStat, Inc. (OTCQB: MTST) is a development stage life sciences company headquartered in Montclair, New Jersey. We are focused on developing and commercializing novel diagnostic technologies and therapeutics for the early and reliable prediction and treatment of systemic metastasis - cancer that spreads from a primary tumor through the bloodstream to other areas of the body. Systemic metastasis is responsible for ~90% of all solid tumor cancer related deaths and as such, we believe that more effective treatment of metastatic disease and/or the prevention of systemic metastasis is needed to improve patient outcomes.
Our licensed proprietary platform technologies are based on the identification of a common pathway for the development of metastatic disease in solid epithelial-based tumors. These discoveries are the result of over 15 years of collaboration with four scientific/academic institutions that enabled us to understand the underlying biology and mechanisms of systemic metastasis. Central to these discoveries are i) the “MetaSite™,” the micro-anatomical site, or “window” in the blood vessels that metastatic cells squeeze through to enter the blood stream to begin their deadly spread, and ii) the pivotal role of the Mena protein and its isoforms in the metastatic cascade.
We are developing two function-based diagnostic product lines, MetaSite Breast™ and MenaCalc™. The MetaSite Breast™ test measures the process of systemic metastasis and is intended for early stage breast cancer patients. MenaCalc™, a platform of diagnostic assays, based on the measurement of the balance of the Mena protein isoforms, is broadly applicable in solid epithelial-based cancers, including breast, prostate, lung and colorectal. Both our MetaSite Breast™ and MenaCalc™ diagnostics are designed to accurately predict the probability of systemic metastasis and to allow clinicians to better "customize" cancer treatment decisions by positively identifying patients with a high-risk of systemic metastasis who need aggressive therapy and by sparing patients with a low-risk of systemic metastasis from the harmful side effects and expense of chemotherapy.
Additionally, we are developing our MenaBloc™ therapeutic platform, with the goal of discovering inhibitors of key pathways that can be advanced as anti-cancer therapeutics in multiple epithelial-based tumor types.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |